| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 01/16/2003 | US20030013766 Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR Modulators |
| 01/16/2003 | US20030013762 6-methoxy-2-naphthylacetic acid prodrugs |
| 01/16/2003 | US20030013761 Use of fumaric acid derivatives for treating mitochondrial diseases |
| 01/16/2003 | US20030013757 Aromatic dicarboxylic acid derivatives |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013751 Viricides; enzyme inhibitors |
| 01/16/2003 | US20030013745 Urazole compounds useful as anti-inflammatory agents |
| 01/16/2003 | US20030013739 Synergistic mixtures; side effect reduction |
| 01/16/2003 | US20030013737 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 01/16/2003 | US20030013734 Skin disorders, immunology diseases, wound healing agents, antiulcer agents |
| 01/16/2003 | US20030013733 Antihistamines, sleep disorders, central nervous system disorders |
| 01/16/2003 | US20030013730 Preventing diarrhea |
| 01/16/2003 | US20030013728 Inhibitors of thrombin induced platelet aggregation |
| 01/16/2003 | US20030013727 Therapy for sexual disorders |
| 01/16/2003 | US20030013726 Sleep disorders; anxiolytic agents; muscle disease |
| 01/16/2003 | US20030013724 Novel prolines as antimicrobial agents |
| 01/16/2003 | US20030013723 Novel urokinase inhibitors |
| 01/16/2003 | US20030013720 Antidiabetic agents; obesity |
| 01/16/2003 | US20030013719 Ortho, meta-substituted bisaryl compounds, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them |
| 01/16/2003 | US20030013718 Phthalazine derivatives for treating inflammatory diseases |
| 01/16/2003 | US20030013717 Cyclooxygenase inhibitor |
| 01/16/2003 | US20030013716 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013712 Antiinflammatory agents |
| 01/16/2003 | US20030013708 Therapeutic heterocyclic compounds |
| 01/16/2003 | US20030013707 Enzyme inhibitor |
| 01/16/2003 | US20030013706 Autoimmune disease; antiinflammatory agents |
| 01/16/2003 | US20030013704 Adamantane derivatives |
| 01/16/2003 | US20030013702 Agents and methods for treatment of cancer |
| 01/16/2003 | US20030013697 Agonizing dimeric cell-surface receptors with a receptor binding moiety and chelating metal |
| 01/16/2003 | US20030013687 Pharmaceutical compositions and methods for treating anxiety, anxiety disorders and memory impairment using NAALADase inhibitors |
| 01/16/2003 | US20030013681 Complexing with galectins |
| 01/16/2003 | US20030013667 Therapeutic agent for ischemia which inhibits apoptosis under ischemic condition |
| 01/16/2003 | US20030013660 Dioxolane analogs for improved inter-cellular delivery |
| 01/16/2003 | US20030013658 Small peptides and methods for treatment of asthma and inflammation |
| 01/16/2003 | US20030013652 Releasing moderators for inflammation |
| 01/16/2003 | US20030013642 Hemoglobin-haptoglobin complexes |
| 01/16/2003 | US20030013638 P27 prevents cellular migration |
| 01/16/2003 | US20030013194 Prevention of membrane formation; obtain cell tissue, incubate with inhibitory collagen, monitor membrane formation |
| 01/16/2003 | US20030013179 Enzymatic polypeptide for use in the treatment of lysosomal storage disorders |
| 01/16/2003 | US20030013144 Detection of modulator of cancer activity; obtain sample containing biopolymers, incubate with modulator, monitor cellular response |
| 01/16/2003 | US20030012812 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 01/16/2003 | US20030012793 Purified complex of heat shock protein noncovalently bound to a molecule. |
| 01/16/2003 | US20030012790 Especially bispecific molecules comprising an IFN- gamma inhibitor and a further specificity to a target involved in the initiation or development of IBD, including ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012787 Especially for ulcerative colitis and Crohn's disease. |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012781 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 01/16/2003 | US20030012779 Reducing the residual solvent content to a level effective to protect said preparation of monoclonal immunoglobulins from said radiation; optionally adding a stabilizer; and irradiating with a suitable radiation |
| 01/16/2003 | US20030012774 Mixture of gamma-cyclodextrin and coenzyme Q1O is treated by homogenisation and inputting energy. |
| 01/16/2003 | US20030012772 Methods for improving cell line activity in immunoisolation devices |
| 01/16/2003 | US20030012770 Recombinant p53 adenovirus methods and compositions |
| 01/16/2003 | US20030012740 Aerosols especially containing benzotropine, pergolide, ropinerole, amantadine or deprenyl. |
| 01/16/2003 | US20030012737 Delivery of diphenhydramine through an inhalation route |
| 01/16/2003 | US20030012325 Mixture containing rare earth and the use thereof |
| 01/16/2003 | US20030010715 Use of cationic exchange chromatography on solid matrix carried out at basic pH |
| 01/16/2003 | CA2490386A1 Method for producing analgesia comprising administration of an opioid receptor agonist in rotation with an opioid receptor like-1 receptor agonist |
| 01/16/2003 | CA2454613A1 Substituted anilinic piperidines as mch selective antagonists |
| 01/16/2003 | CA2453572A1 The use of derivatives of 2,5-dihydroxybenxenesulphonic acids in the elaboration of a medicinal product to enhance the effect of other drugs used for the treatment of erectile disfunction |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452686A1 Arylamines for the treatment of conditions associated with gsk-3 |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2452592A1 4-aryl quinols and analogs thereof as therapeutic agents |
| 01/16/2003 | CA2452590A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | CA2452501A1 Secreted proteins |
| 01/16/2003 | CA2452392A1 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | CA2452372A1 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 01/16/2003 | CA2452366A1 Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2452211A1 Cycloalkylpyrrole-3-carboxylic acid derivatives and heterocycloalkylpyrrole-3-carboxylic acid derivatives as gaba-a receptor ligands |
| 01/16/2003 | CA2451749A1 Novel immunomodulating compounds |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451606A1 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | CA2451391A1 C12 modified erythromycin macrolides and ketolides having antibacterial activity |
| 01/16/2003 | CA2451374A1 Aggrecanase molecules |
| 01/16/2003 | CA2451092A1 Identification of modulators of neurotransmitter activity of xanthurenic acid |
| 01/16/2003 | CA2450857A1 Compounds having prolyl oligopeptidase inhibitory activity, methods for their preparation and their use |
| 01/16/2003 | CA2450236A1 Phage displayed pdz domain ligands |
| 01/15/2003 | EP1275733A2 Assay methods for peptidase modulators |
| 01/15/2003 | EP1275720A2 Histidyl-trna synthetase of staphylococcus aureus |
| 01/15/2003 | EP1275713A1 Tlr/cd14 binding inhibitor |
| 01/15/2003 | EP1275657A1 Peptide derivatives and medicinal compositions |
| 01/15/2003 | EP1275647A1 Octahydro-2H-pyrido[1,2-a]pyrazine derivatives, process for their preparation and pharmaceutical compositions containing them |
| 01/15/2003 | EP1275646A1 Indolylpyrrole derivatives and cell death inhibitors |
| 01/15/2003 | EP1275400A1 Therapeutic composition of non MHC-restricted T-cells/NK-cells and MHC-restricted cells for the treatment of tumors |
| 01/15/2003 | EP1275398A1 Diagnostics and remedies for rheumatoid arthritis |
| 01/15/2003 | EP1275396A2 Use of angiotensin II fragments and analogs thereof in tissue repair |
| 01/15/2003 | EP1275391A1 Pharmaceutical compositions containing irbesartan and a diuretic |
| 01/15/2003 | EP1275388A1 Tnf- alpha inhibitors |
| 01/15/2003 | EP1275372A1 Cosmetic or dermatological composition comprising a N-acylaminoamide derivative and a metalloproteinase inhibitor |
| 01/15/2003 | EP1274980A1 Solution and crystal structures of mmp-13 active site and uses thereof |
| 01/15/2003 | EP1274849A2 Protein phosphatases |
| 01/15/2003 | EP1274842A2 Lipid binding protein 4 |
| 01/15/2003 | EP1274834A1 HUMAN AMINOACYL-tRNA SYNTHETASE POLYPEPTIDES USEFUL FOR THE REGULATION OF ANGIOGENESIS |
| 01/15/2003 | EP1274726A2 Therapeutic compounds and methods for modulating v3, a versican isoform |
| 01/15/2003 | EP1274724A2 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties |
| 01/15/2003 | EP1274720A1 Albumin fusion proteins |
| 01/15/2003 | EP1274719A2 Albumin fusion proteins |
| 01/15/2003 | EP1274710A2 Novel heteroaryl-diazabicycloalkanes |